Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol 2005 Nov 01;23(31):8124-5; author reply 8125-6
Date
11/01/2005Pubmed ID
16258115DOI
10.1200/JCO.2005.03.2458Scopus ID
2-s2.0-32944469067 (requires institutional sign-in at Scopus site) 2 CitationsAuthor List
Stadler WM, Michaelis LC, Ratain MJAuthor
Laura Michaelis MD Chief, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, Tumor
Clinical Trials, Phase II as Topic
Humans
Male
Neoplasms, Hormone-Dependent
Prostate-Specific Antigen
Prostatic Neoplasms
Randomized Controlled Trials as Topic
Treatment Outcome